Fowlpox viruses (FPV) are attractive platform vaccine vector candidates because their capacity for insertion of multiple heterologous genes makes them favourable for genetic modification. They also have strong adjuvant activity in their own right. As FPV does not replicate in mammalian cells, there is significantly less opposition associated with their clinical application, with a number already in use. However, a thorough understanding of the immunological relationship between FPV and the mammalian immune system is still lacking. The aim of this thesis was to construct a series of recombinant FPV vectors that co-expressed the nominal antigen chicken ovalbumin (OVA), (FPV[subscript]OVA), and/or murine interleukin-4 (mIL-4). These constructs were used for the characterisation of the relationship between FPV and the mammalian immune system and how this is altered by the co-expression of mIL-4. Immunisation with FPV[subscript]OVA resulted in rapid and highly localized OVA expression which induced strong CD8⁺ cytotoxic T cell (CTL) activity but only weak CD4⁺ T helper and antibody responses. In addition, presentation of FPV-derived antigen and the priming of antigen-specific CTL responses required a permissive bone marrow (BM)-derived cell as the antigen presenting cell (APC). Co-administration with FPV[subscript]mIL-4 resulted in a dramatic reduction in CTL activity that remained largely non-functional throughout the infection and a skewing of the T helper (Th) response towards Th2 with a reduction in interferon (IFN)-γ production by OVA-specific Th cells. These findings provide a sound basis for further characterization of how FPV interacts with the innate and adaptive arms of the immune system, how these can be manipulated via the co-administration of cytokines, and discovering if future rationally designed modifications result in FPV vectored vaccines that induce durable cellular and humoral immunity. / http://proxy.library.adelaide.edu.au/login?url= http://library.adelaide.edu.au/cgi-bin/Pwebrecon.cgi?BBID=1352466 / Thesis (M.Med.Sc.) - University of Adelaide, School of Medicine, 2009

Fowlpox viruses (FPV) are attractive platform vaccine vector candidates because their capacity for insertion of multiple heterologous genes makes them favourable for genetic modification. They also have strong adjuvant activity in their own right. As FPV does not replicate in mammalian cells, there is significantly less opposition associated with their clinical application, with a number already in use. However, a thorough understanding of the immunological relationship between FPV and the mammalian immune system is still lacking. The aim of this thesis was to construct a series of recombinant FPV vectors that co-expressed the nominal antigen chicken ovalbumin (OVA), (FPV[subscript]OVA), and/or murine interleukin-4 (mIL-4). These constructs were used for the characterisation of the relationship between FPV and the mammalian immune system and how this is altered by the co-expression of mIL-4. Immunisation with FPV[subscript]OVA resulted in rapid and highly localized OVA expression which induced strong CD8⁺ cytotoxic T cell (CTL) activity but only weak CD4⁺ T helper and antibody responses. In addition, presentation of FPV-derived antigen and the priming of antigen-specific CTL responses required a permissive bone marrow (BM)-derived cell as the antigen presenting cell (APC). Co-administration with FPV[subscript]mIL-4 resulted in a dramatic reduction in CTL activity that remained largely non-functional throughout the infection and a skewing of the T helper (Th) response towards Th2 with a reduction in interferon (IFN)-γ production by OVA-specific Th cells. These findings provide a sound basis for further characterization of how FPV interacts with the innate and adaptive arms of the immune system, how these can be manipulated via the co-administration of cytokines, and discovering if future rationally designed modifications result in FPV vectored vaccines that induce durable cellular and humoral immunity. / http://proxy.library.adelaide.edu.au/login?url= http://library.adelaide.edu.au/cgi-bin/Pwebrecon.cgi?BBID=1352466 / Thesis (M.Med.Sc.) - University of Adelaide, School of Medicine, 2009

Fowlpox viruses (FPV) are attractive platform vaccine vector candidates because their capacity for insertion of multiple heterologous genes makes them favourable for genetic modification. They also have strong adjuvant activity in their own right. As FPV does not replicate in mammalian cells, there is significantly less opposition associated with their clinical application, with a number already in use. However, a thorough understanding of the immunological relationship between FPV and the mammalian immune system is still lacking. The aim of this thesis was to construct a series of recombinant FPV vectors that co-expressed the nominal antigen chicken ovalbumin (OVA), (FPV[subscript]OVA), and/or murine interleukin-4 (mIL-4). These constructs were used for the characterisation of the relationship between FPV and the mammalian immune system and how this is altered by the co-expression of mIL-4. Immunisation with FPV[subscript]OVA resulted in rapid and highly localized OVA expression which induced strong CD8⁺ cytotoxic T cell (CTL) activity but only weak CD4⁺ T helper and antibody responses. In addition, presentation of FPV-derived antigen and the priming of antigen-specific CTL responses required a permissive bone marrow (BM)-derived cell as the antigen presenting cell (APC). Co-administration with FPV[subscript]mIL-4 resulted in a dramatic reduction in CTL activity that remained largely non-functional throughout the infection and a skewing of the T helper (Th) response towards Th2 with a reduction in interferon (IFN)-γ production by OVA-specific Th cells. These findings provide a sound basis for further characterization of how FPV interacts with the innate and adaptive arms of the immune system, how these can be manipulated via the co-administration of cytokines, and discovering if future rationally designed modifications result in FPV vectored vaccines that induce durable cellular and humoral immunity. / http://proxy.library.adelaide.edu.au/login?url= http://library.adelaide.edu.au/cgi-bin/Pwebrecon.cgi?BBID=1352466 / Thesis (M.Med.Sc.) - University of Adelaide, School of Medicine, 2009

Master of Science / Department of Anatomy and Physiology / Jishu Shi / The development of reverse genetics systems for the manipulation of viral and bacterial genomes has provided platforms for identifying virulence genes, studying pathogenesis and developing vaccines. Replication-competent vaccines (e.g., modified live virus (MLV) vaccines and replicating viral/bacterial vectors) are considered the most efficacious approach for vaccine development. We constructed replication-competent candidate vaccines for two viral diseases in pigs via reverse genetics. The first vaccine we designed is to protect against highly pathogenic porcine reproductive and respiratory syndrome virus (HP-PRRSV). HP-PRRSV can cause high mortality in pigs of all ages. Vaccines to protect pigs from HP-PRRSV are not commercially available in the US. According to previous studies, the non-structural protein (NSP) coding region of HP-PRRSV is closely related to the high mortality rate and the structural protein (SP) coding region contributes to the induction of broadly protective neutralizing antibodies. We created a chimeric PRRSV, of which the SP coding region was derived from HP-PRRSV and NSP coding region was derived from a low-pathogenic strain. This chimeric PRRSV caused similar CPE in cells as parental viruses, but had slower growth kinetics. We hypothesize that this chimeric virus will have a low pathogenicity and could serve as a candidate vaccine that can provide protection against HP-PRRV. The second vaccine vector is a modified Listeria innocua (L.inn), a non-pathogenic strain of Listeria. Genetically related Listeria monocytogenes (L.m) is a well-known intracellular pathogen that encodes specialized virulent determinants facilitating its intracellular growth and spread. Our goal is to make L.inn a vaccine vector that can deliver classical swine fever (CSF) viral antigen into intracellular environments by complementation of L.inn with selected L.m virulence genes necessary for intracellular survival and induction of a robust immune response. In this study, we constructed a shuttle vector pHT-E2 that can express CSFV antigen E2 in L.inn. We cloned the plcA-prfA operon of L.m virulence gene cluster (vgc) into pHT-E2, which enhanced the expression of E2 in L.inn. In future studies, we plan to clone additional L.m virulence genes into the shuttle vector to increase immunogenicity of this recombinant L.inn and test its ability to protect pigs from CSFV.

The purpose of this study is to characterise Australian isolates of bovine enterovirus (BEV) and develop a suitable isolate as a replication-limited vaccine vector. Advantages of using BEV as a vector are that it both elicits mucosal immunity and has naturally occurring temperature stable isolates so that a BEV vector could be administered orally to elicit a protective immune response in the host and should not require cold storage to maintain vaccine efficacy. Furthermore, wildtype BEV causes no or only mild clinical symptoms in its host and if BEV is used as a vaccine vector, reversion to wildtype phenotype would not cause deleterious effects in vaccinated cattle. To date many of the viruses used as vaccine vectors are produced by modifying the structural proteins of the virion so that they contain heterologous sequences. However, each of the four BEV structural proteins are essential and it is not possible to insert large sequences without disrupting the virion. While this study looks at potential insertion sites within the BEV virion, the main focus for the development of BEV as a vaccine vector is through using a replication-limited BEV vector. The development of a replication-limited vector requires the deletion of an essential viral gene that is then replaced in vitro using an expression vector. When the replication-limited vector and its complementing expression cassette are co-transfected into a permissive cell line all the proteins required for viral assembly are produced but only replication deficient genomes are available to be encapsidated. The physically intact but replication deficient viral particles produced in vitro can then infect permissive cells in vivo, resulting in the production of all but the deleted viral protein. Moreover, the deleted portion of the viral genome can be replaced with heterologous sequences within the replication-limited BEV vector. These heterologous sequences can then be expressed in vivo where they can be recognised by the host immune system. Three BEV isolates representing the Australian subserotypes were used in this study: K2577, SL305 and 66/27. The full-length sequences of K2577 and SL305 were obtained as well as partial sequence from the third isolate, 66/27. Sequence homology and phylogenetic analysis showed all three isolates were more closely related to BEV-1 subserotypes than BEV-2. This is the first report to indicate that Australian BEV isolates can be classified as BEV-1. Analysis of the 5’-untranslated region (5’-UTR) indicated that BEV isolates were recombinants with each other and that these recombinant regions correspond to the duplicated cloverleaf structure which is present in BEV 5’-UTR but absent from other enteroviruses. While BEV was initially reported to be stable at higher temperatures, later studies showed that this property varied between isolates and this is also true of the three isolates used in this study. Since it is important not only to ensure that the isolate used as a vaccine vector is temperature stable but also the resulting vaccine vector, the molecular basis of BEV temperature stability was also studied. Using sequence data from the Australian isolates, regions of variation were located and hybrid BEV created. Unfortunately, all of the hybrid BEV produced in this study were non-infectious and could not be used to for further characterisation of BEV temperature stability. Preparatory to constructing replication-limited BEV, a system for full-length amplification of BEV was developed. By including sequences for the bacterial promoter T7 on the positive sense primer used for full-length amplification of BEV, it was possible to prepare full-length transcripts of the amplified product and these were shown to produce infectious BEV particles when transfected into to cell lines that supported BEV growth. Subsequent cloning of the K2577 amplification product resulted in infectious clones for this BEV isolate and these clones were used to prepare replication-limited BEV constructs. To test the replication-limited system BEV structural genes were replaced with a reporter gene to produce replication deficient infectious clones. Complementary constructs containing only the deleted structural genes were also prepared to express the deleted genes. While it was expected that these expression vector would be able to complement the replication deficient BEV in vivo, co-transfection of the replication-limited construct with its complementing expression vector did not produce viable BEV.

The purpose of this study is to characterise Australian isolates of bovine enterovirus (BEV) and develop a suitable isolate as a replication-limited vaccine vector. Advantages of using BEV as a vector are that it both elicits mucosal immunity and has naturally occurring temperature stable isolates so that a BEV vector could be administered orally to elicit a protective immune response in the host and should not require cold storage to maintain vaccine efficacy. Furthermore, wildtype BEV causes no or only mild clinical symptoms in its host and if BEV is used as a vaccine vector, reversion to wildtype phenotype would not cause deleterious effects in vaccinated cattle. To date many of the viruses used as vaccine vectors are produced by modifying the structural proteins of the virion so that they contain heterologous sequences. However, each of the four BEV structural proteins are essential and it is not possible to insert large sequences without disrupting the virion. While this study looks at potential insertion sites within the BEV virion, the main focus for the development of BEV as a vaccine vector is through using a replication-limited BEV vector. The development of a replication-limited vector requires the deletion of an essential viral gene that is then replaced in vitro using an expression vector. When the replication-limited vector and its complementing expression cassette are co-transfected into a permissive cell line all the proteins required for viral assembly are produced but only replication deficient genomes are available to be encapsidated. The physically intact but replication deficient viral particles produced in vitro can then infect permissive cells in vivo, resulting in the production of all but the deleted viral protein. Moreover, the deleted portion of the viral genome can be replaced with heterologous sequences within the replication-limited BEV vector. These heterologous sequences can then be expressed in vivo where they can be recognised by the host immune system. Three BEV isolates representing the Australian subserotypes were used in this study: K2577, SL305 and 66/27. The full-length sequences of K2577 and SL305 were obtained as well as partial sequence from the third isolate, 66/27. Sequence homology and phylogenetic analysis showed all three isolates were more closely related to BEV-1 subserotypes than BEV-2. This is the first report to indicate that Australian BEV isolates can be classified as BEV-1. Analysis of the 5’-untranslated region (5’-UTR) indicated that BEV isolates were recombinants with each other and that these recombinant regions correspond to the duplicated cloverleaf structure which is present in BEV 5’-UTR but absent from other enteroviruses. While BEV was initially reported to be stable at higher temperatures, later studies showed that this property varied between isolates and this is also true of the three isolates used in this study. Since it is important not only to ensure that the isolate used as a vaccine vector is temperature stable but also the resulting vaccine vector, the molecular basis of BEV temperature stability was also studied. Using sequence data from the Australian isolates, regions of variation were located and hybrid BEV created. Unfortunately, all of the hybrid BEV produced in this study were non-infectious and could not be used to for further characterisation of BEV temperature stability. Preparatory to constructing replication-limited BEV, a system for full-length amplification of BEV was developed. By including sequences for the bacterial promoter T7 on the positive sense primer used for full-length amplification of BEV, it was possible to prepare full-length transcripts of the amplified product and these were shown to produce infectious BEV particles when transfected into to cell lines that supported BEV growth. Subsequent cloning of the K2577 amplification product resulted in infectious clones for this BEV isolate and these clones were used to prepare replication-limited BEV constructs. To test the replication-limited system BEV structural genes were replaced with a reporter gene to produce replication deficient infectious clones. Complementary constructs containing only the deleted structural genes were also prepared to express the deleted genes. While it was expected that these expression vector would be able to complement the replication deficient BEV in vivo, co-transfection of the replication-limited construct with its complementing expression vector did not produce viable BEV.

The purpose of this study is to characterise Australian isolates of bovine enterovirus (BEV) and develop a suitable isolate as a replication-limited vaccine vector. Advantages of using BEV as a vector are that it both elicits mucosal immunity and has naturally occurring temperature stable isolates so that a BEV vector could be administered orally to elicit a protective immune response in the host and should not require cold storage to maintain vaccine efficacy. Furthermore, wildtype BEV causes no or only mild clinical symptoms in its host and if BEV is used as a vaccine vector, reversion to wildtype phenotype would not cause deleterious effects in vaccinated cattle. To date many of the viruses used as vaccine vectors are produced by modifying the structural proteins of the virion so that they contain heterologous sequences. However, each of the four BEV structural proteins are essential and it is not possible to insert large sequences without disrupting the virion. While this study looks at potential insertion sites within the BEV virion, the main focus for the development of BEV as a vaccine vector is through using a replication-limited BEV vector. The development of a replication-limited vector requires the deletion of an essential viral gene that is then replaced in vitro using an expression vector. When the replication-limited vector and its complementing expression cassette are co-transfected into a permissive cell line all the proteins required for viral assembly are produced but only replication deficient genomes are available to be encapsidated. The physically intact but replication deficient viral particles produced in vitro can then infect permissive cells in vivo, resulting in the production of all but the deleted viral protein. Moreover, the deleted portion of the viral genome can be replaced with heterologous sequences within the replication-limited BEV vector. These heterologous sequences can then be expressed in vivo where they can be recognised by the host immune system. Three BEV isolates representing the Australian subserotypes were used in this study: K2577, SL305 and 66/27. The full-length sequences of K2577 and SL305 were obtained as well as partial sequence from the third isolate, 66/27. Sequence homology and phylogenetic analysis showed all three isolates were more closely related to BEV-1 subserotypes than BEV-2. This is the first report to indicate that Australian BEV isolates can be classified as BEV-1. Analysis of the 5’-untranslated region (5’-UTR) indicated that BEV isolates were recombinants with each other and that these recombinant regions correspond to the duplicated cloverleaf structure which is present in BEV 5’-UTR but absent from other enteroviruses. While BEV was initially reported to be stable at higher temperatures, later studies showed that this property varied between isolates and this is also true of the three isolates used in this study. Since it is important not only to ensure that the isolate used as a vaccine vector is temperature stable but also the resulting vaccine vector, the molecular basis of BEV temperature stability was also studied. Using sequence data from the Australian isolates, regions of variation were located and hybrid BEV created. Unfortunately, all of the hybrid BEV produced in this study were non-infectious and could not be used to for further characterisation of BEV temperature stability. Preparatory to constructing replication-limited BEV, a system for full-length amplification of BEV was developed. By including sequences for the bacterial promoter T7 on the positive sense primer used for full-length amplification of BEV, it was possible to prepare full-length transcripts of the amplified product and these were shown to produce infectious BEV particles when transfected into to cell lines that supported BEV growth. Subsequent cloning of the K2577 amplification product resulted in infectious clones for this BEV isolate and these clones were used to prepare replication-limited BEV constructs. To test the replication-limited system BEV structural genes were replaced with a reporter gene to produce replication deficient infectious clones. Complementary constructs containing only the deleted structural genes were also prepared to express the deleted genes. While it was expected that these expression vector would be able to complement the replication deficient BEV in vivo, co-transfection of the replication-limited construct with its complementing expression vector did not produce viable BEV.

Please read the abstract in the section 00front of this document / Thesis (PhD (Genetics))--University of Pretoria, 2007. / Genetics / unrestricted

Bovine herpesvirus-1 (BoHV-1) is an important pathogen of cattle associated with respiratory and reproductive disease and is the most common viral agent implicated in the bovine respiratory disease complex (BRDC). BRDC is an economically significant multifactorial disease of feedlot cattle estimated to cost Australian feedlot producers $AU60 million/year in lost production, therapeutics and disease management. Worldwide BRDC is attributed to cost $US2 billion to cattle industries. In an effort to limit the associated economic costs and enhance animal health and welfare of feedlot cattle, the concerted use of vaccination and diseased animal management are practiced. Numerous vaccines are available in North America and Canada however, in Australia, feedlot producers are reliant on three vaccines. These vaccines target either the bacterial or viral agents of the BRDC and encompass antibody, subunit and attenuated live BoHV-1 preparations. Live attenuated vaccines are developed by numerous methods including, deletion or disruption of certain genes. The development of an attenuated live virus vaccine was traditionally a laborious task requiring numerous rounds of in vitro purification. Contrastingly, technological advances introduced this decade, allowing the stable maintenance of the complete herpesvirus genome in bacteria as a bacterial artificial chromosome (BAC), has advanced herpes virology exponentially in that investigation and manipulation of the herpesvirus genome can be conducted independent of a cell culture system. With respect to BRDC and the generation of vaccines to combat the disease, the tools to fully utilise the potential of BoHV-1 as a live vaccine vector are now routine. It is now possible to vii construct BoHV-1 as a delivery vector by inserting appropriate antigens of those bacterial and viral pathogens implicated in the BRDC into a BAC maintained BoHV-1 genome. However, there is a significant lack of genetic information regarding BoHV-1 and inserting several antigenic sequences would expand the genome of BoHV-1 inducing non-viability. Therefore, to further develop BoHV-1 as a vaccine vector, a study was conducted to identify the essential and nonessential genes required for the in vitro viability of BoHV-1. Identifying the essential and nonessential genes will establish which genes may be preferentially deleted or replaced with exogenous antigenic sequences in a BoHV-1 derived vaccine vector. To define the requirement of genes encoded by BoHV-1, random-insertion mutagenesis utilising a Tn5 transposition system and targeted gene deletion catalysed by GET recombination was employed to construct gene disruption and gene deletion libraries, respectively, of an infectious clone of BoHV-1. Transposon insertion position and confirmation of gene deletion was determined by direct sequencing. with the essential or nonessential requirement of either transposed or deleted open reading frames (ORFs) assessed by transfection of respective BoHV- 1 BAC DNA into host cells. Of the 73 recognised ORFs encoded by the BoHV-1 genome, 33 were determined to be essential and 36 to be nonessential for virus viability in cell culture with the requirement of the two dual copy ORFs inconclusive. The majority of ORFs were shown to conform to the in vitro requirements of BoHV-1 homologues encoded by Human herpesvirus 1. However, ORFs encoding for glycoprotein K (UL53), regulatory, membrane, tegument and capsid proteins (UL54, UL49.5, UL49, UL35, UL20, UL16 and UL7) were shown to differ in requirement when compared to Human herpesvirus-1 encoded homologues. Further analysis of clones encompassing restriction digestion profiling, one-step growth and replication kinetic analysis defined the genetic constitution and replicative capacity of the mutant clones. Thirty-three individual ORFs of the 36 defined nonessential ORF were identified as being amenable to deletion without causing significant replicative detriment to a potential BoHV-1 vaccine vector. This study has provided the foundational information required for the future development of BoHV-1 as a multivalent vaccine vector for the protection of feedlot cattle from BRDC. Furthermore, the genetic information generated in this study contributes to the general knowledge of the prototype ruminant herpesvirus, BoHV-1, and contributes to the comparative study of gene function between the large and diverse family that is Herpesviridae.

Bovine herpesvirus-1 (BoHV-1) is an important pathogen of cattle associated with respiratory and reproductive disease and is the most common viral agent implicated in the bovine respiratory disease complex (BRDC). BRDC is an economically significant multifactorial disease of feedlot cattle estimated to cost Australian feedlot producers $AU60 million/year in lost production, therapeutics and disease management. Worldwide BRDC is attributed to cost $US2 billion to cattle industries. In an effort to limit the associated economic costs and enhance animal health and welfare of feedlot cattle, the concerted use of vaccination and diseased animal management are practiced. Numerous vaccines are available in North America and Canada however, in Australia, feedlot producers are reliant on three vaccines. These vaccines target either the bacterial or viral agents of the BRDC and encompass antibody, subunit and attenuated live BoHV-1 preparations. Live attenuated vaccines are developed by numerous methods including, deletion or disruption of certain genes. The development of an attenuated live virus vaccine was traditionally a laborious task requiring numerous rounds of in vitro purification. Contrastingly, technological advances introduced this decade, allowing the stable maintenance of the complete herpesvirus genome in bacteria as a bacterial artificial chromosome (BAC), has advanced herpes virology exponentially in that investigation and manipulation of the herpesvirus genome can be conducted independent of a cell culture system. With respect to BRDC and the generation of vaccines to combat the disease, the tools to fully utilise the potential of BoHV-1 as a live vaccine vector are now routine. It is now possible to vii construct BoHV-1 as a delivery vector by inserting appropriate antigens of those bacterial and viral pathogens implicated in the BRDC into a BAC maintained BoHV-1 genome. However, there is a significant lack of genetic information regarding BoHV-1 and inserting several antigenic sequences would expand the genome of BoHV-1 inducing non-viability. Therefore, to further develop BoHV-1 as a vaccine vector, a study was conducted to identify the essential and nonessential genes required for the in vitro viability of BoHV-1. Identifying the essential and nonessential genes will establish which genes may be preferentially deleted or replaced with exogenous antigenic sequences in a BoHV-1 derived vaccine vector. To define the requirement of genes encoded by BoHV-1, random-insertion mutagenesis utilising a Tn5 transposition system and targeted gene deletion catalysed by GET recombination was employed to construct gene disruption and gene deletion libraries, respectively, of an infectious clone of BoHV-1. Transposon insertion position and confirmation of gene deletion was determined by direct sequencing. with the essential or nonessential requirement of either transposed or deleted open reading frames (ORFs) assessed by transfection of respective BoHV- 1 BAC DNA into host cells. Of the 73 recognised ORFs encoded by the BoHV-1 genome, 33 were determined to be essential and 36 to be nonessential for virus viability in cell culture with the requirement of the two dual copy ORFs inconclusive. The majority of ORFs were shown to conform to the in vitro requirements of BoHV-1 homologues encoded by Human herpesvirus 1. However, ORFs encoding for glycoprotein K (UL53), regulatory, membrane, tegument and capsid proteins (UL54, UL49.5, UL49, UL35, UL20, UL16 and UL7) were shown to differ in requirement when compared to Human herpesvirus-1 encoded homologues. Further analysis of clones encompassing restriction digestion profiling, one-step growth and replication kinetic analysis defined the genetic constitution and replicative capacity of the mutant clones. Thirty-three individual ORFs of the 36 defined nonessential ORF were identified as being amenable to deletion without causing significant replicative detriment to a potential BoHV-1 vaccine vector. This study has provided the foundational information required for the future development of BoHV-1 as a multivalent vaccine vector for the protection of feedlot cattle from BRDC. Furthermore, the genetic information generated in this study contributes to the general knowledge of the prototype ruminant herpesvirus, BoHV-1, and contributes to the comparative study of gene function between the large and diverse family that is Herpesviridae.